secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001437749-24-026888
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals secures up to $16M senior secured debt from Anson Funds; settles Streeterville claims
--------------------------------------------------------------------------------

- Up to $16.3M principal in three tranches; first tranche $5.435M principal at $5M purchase price.
- Notes convertible at lower of $2.4168 or 92% of lowest VWAP; 6% interest, 15-month maturity.
- Warrants for 50% of principal/VWAP, 5-year term, exercise at $2.4168 with potential adjustments.
- Proceeds to fund 2024 NDA filings for NRX-100 (ketamine) and NRX-101; retire Streeterville debt.
- Streeterville settlement: $2.5M at closing plus $3.05M within 60 days; all claims released.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/0001437749-24-026888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924026888/nrxp20240813_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer